[ad_1]
This is the first ARV combined with this type of the type to be offered to patients treated for HIV. It will be available as a first-line treatment for people living with HIV / AIDS.
The company, Mylan, said the drug would greatly help people on ARVs cope with major changes, including reducing the number of pills taken and improving the effectiveness of antiretrovirals.
TLD combines three of the leading front-line agents into a new smaller tablet that patients can take once a day.
Rakesh Bamzai, Mylan's President for India and Emerging Markets, said, "Mylan's global HIV initiative is one of society's top priorities.
"The launch of TLDs in South Africa reinforces our longstanding commitment to the fight against HIV / AIDS and supports our mission to expand access to high quality medicines to more people."
He noted that HIV is a public health priority for South Africa and other countries of the world.
"We are proud of the progress we have made to date to stem the tide of disease. More than 40% of the nearly 21 million HIV patients treated today – and 60% of HIV-positive children worldwide – depend daily on one of Mylan's products. "
UNAids said that, according to its statistics, the number of new infections has decreased by 49% and the number of AIDS-related deaths by 29% since 2010.
South Africa has the largest treatment program in the world, accounting for 20% of people on antiretroviral therapy worldwide.
The country also has one of the largest programs funded by the country, with about 80 percent of the AIDS response being funded by the government.
"In 2000, only 685,000 people living with HIV had access to antiretroviral therapy.
"In June 2017, about 20.9 million people had access to life-saving medicines.
"Such a dramatic rise could not have happened without the courage and determination of people living with HIV who claim and claim their rights, backed by strong and consistent leadership and financial commitment," he said. UNAids.
[ad_2]
Source link
